April 26, 2019
April 28, 2021
The aim of this study is to compare two different pain management interventions in patients undergoing reverse total shoulder arthroplasty. The two interventions are 1) pre-operative interscalene nerve block and 2) intraoperative injection of liposomal bupivacaine (Exparel, Pacira Pharmaceuticals, Parsippany NJ). Specifically, the primary aims of this study are to compare these two interventions on the following: post-operative opioid consumption, pain scores, and patient satisfaction. Additionally, the investigators want to determine if psychological factors, catastrophizing and resilience, are associated with post-operative pain control and satisfaction. The investigators' hypothesis is that the two interventions will have similar pain control efficacy and that the liposomal bupivacaine group will experience faster post-operative recovery, earlier discharge, and improved satisfaction. The investigators also expect patient catastrophizing and resilience to significantly predict the degree of post-operative pain and level of patient satisfaction.
|Experimental: Liposomal Bupivacaine
Patients in this group will receive a single intra-operative injection of liposomal bupivacaine near the surgical site (40 ml total: consisting of 20 ml 1.3% liposomal bupivacaine and 20 ml normal saline).
Patients will receive a local injection of liposomal bupivacaine near the end of their shoulder arthroplasty operation.
|Other: Interscalene Nerve Block
Patients in this group will receive a single pre-operative interscalene nerve block in the neck/shoulder consisting of 30 ml 0.5% ropivacaine.
Procedure: Interscalene Nerve Block
Patients will undergo a pre-operative interscalene nerve block performed by the anesthesiology team.
- patients who are older than 18 years
- patients undergoing reverse total shoulder arthroplasty
- inability to provide informed consent
- deemed unreliable for follow-up survey completion
- individuals who do not speak English
- those who have an allergy to the study medications (ropivicaine, bupivicaine) or have
clinically significant hepatic disease
Contact: Adam Schumaier, MD 513-558-4516 email@example.com
Contact: Brian Grawe, MD 513-558-4516 firstname.lastname@example.org
United States, Ohio
University of Cincinnati Medical Center
University of Cincinnati
Principal Investigator: Adam Schumaier, MD University of Cincinnati, Department of Orthopaedics and Sports Medicine